BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22864813)

  • 1. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
    Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE
    Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.
    Sojkova J; Driscoll I; Iacono D; Zhou Y; Codispoti KE; Kraut MA; Ferrucci L; Pletnikova O; Mathis CA; Klunk WE; O'Brien RJ; Wong DF; Troncoso JC; Resnick SM
    Arch Neurol; 2011 Feb; 68(2):232-40. PubMed ID: 21320990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD; Joseph-Mathurin N; Sinha N; Zhou A; Li Y; Friedrichsen K; McCullough A; Franklin EE; Hornbeck R; Gordon B; Sharma V; Cruchaga C; Goate A; Karch C; McDade E; Xiong C; Bateman RJ; Ghetti B; Ringman JM; Chhatwal J; Masters CL; McLean C; Lashley T; Su Y; Koeppe R; Jack C; Klunk WE; Morris JC; Perrin RJ; Cairns NJ; Benzinger TLS
    Acta Neuropathol; 2021 Oct; 142(4):689-706. PubMed ID: 34319442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
    Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
    Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
    Niedowicz DM; Beckett TL; Matveev S; Weidner AM; Baig I; Kryscio RJ; Mendiondo MS; LeVine H; Keller JN; Murphy MP
    Ann Neurol; 2012 Oct; 72(4):564-70. PubMed ID: 23109151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB.
    Ito H; Shinotoh H; Shimada H; Miyoshi M; Yanai K; Okamura N; Takano H; Takahashi H; Arakawa R; Kodaka F; Ono M; Eguchi Y; Higuchi M; Fukumura T; Suhara T
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):745-54. PubMed ID: 24233004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.
    Lowe VJ; Lundt ES; Albertson SM; Przybelski SA; Senjem ML; Parisi JE; Kantarci K; Boeve B; Jones DT; Knopman D; Jack CR; Dickson DW; Petersen RC; Murray ME
    Alzheimers Dement; 2019 Jul; 15(7):927-939. PubMed ID: 31175025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.
    Burack MA; Hartlein J; Flores HP; Taylor-Reinwald L; Perlmutter JS; Cairns NJ
    Neurology; 2010 Jan; 74(1):77-84. PubMed ID: 20038776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology.
    Martersteck A; Ayala I; Ohm DT; Spencer C; Coventry C; Weintraub S; Bigio EH; Mesulam M-; Geula C; Rogalski E
    Acta Neuropathol Commun; 2022 Aug; 10(1):111. PubMed ID: 35945628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease: spect and pet tracers for beta-amyloid imaging.
    Valotassiou V; Archimandritis S; Sifakis N; Papatriantafyllou J; Georgoulias P
    Curr Alzheimer Res; 2010 Sep; 7(6):477-86. PubMed ID: 20455860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.
    Shin J; Lee SY; Kim SH; Kim YB; Cho SJ
    Neuroimage; 2008 Nov; 43(2):236-44. PubMed ID: 18694837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.